SCHEMBL5009769

SCHEMBL5009769

O=C(NCc1ccccc1)c1cc(NC(=O)c2ccc(F)cc2C(F)(F)F)[nH]n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.47
AURKA O14965 1/20 0.42
CHEK2 O96017 1/20 0.42
CSF1R P07333 1/20 0.42
RET P07949 1/20 0.42
FLT4 P35916 1/20 0.42
ABL2 P42684 1/20 0.42
BLK P51451 1/20 0.42
LIMK1 P53667 1/20 0.42
AURKB Q96GD4 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
PTGES O14684 2/20 0.42
ALOX15 P16050 1/20 0.41
MMP13 P45452 1/20 0.41
CNR2 P34972 2/20 0.41
POLB P06746 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008318 0.92 PPARG (0.47) PPARGCYP1A2CYP2C19KMT2APTGES
SCHEMBL5013503 0.87 PPARG (0.50) PPARGCYP1A2CYP2C19KMT2AALOX15
SCHEMBL5013581 0.85 PPARG (0.55) PPARGCYP1A2CYP2C19KMT2AALOX15
SCHEMBL5013518 0.85 HSP90AA1 (0.46) PPARGCYP1A2CYP2C19KMT2AMMP13
SCHEMBL5012227 0.84 HTT (0.47) PPARGCYP1A2CYP2C19KMT2AMMP13
SCHEMBL5013532 0.81 HPGD (0.52) PPARGKMT2APOLBTP53MAPT
Benzamide SCHEMBL27727565 0.80 PTGES (0.48) AURKACHEK2CSF1RRETFLT4
SCHEMBL5010394 0.79 PPARG (0.51) PPARGCYP1A2CYP2C19MMP13POLB
SCHEMBL5010405 0.79 PPARG (0.59) PPARGMMP13
SCHEMBL5013596 0.78 ALDH2 (0.50) PPARGCYP1A2CYP2C19KMT2AMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL PPARG 706/4885AURKA 1817/4885CHEK2 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.